<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="a73e1339-9643-4eea-2cbe-e879c88fb50e"><labelDrug name="ATACAND"><Normalization><mmtx cui="C0718711" preferredWord="Atacand" semType="phsu, orch"/></Normalization></labelDrug><generic name="Candesartan cilexetil"/><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1" text="Drug Label for drug brand ATACAND, containing Candesartan cilexetil." type="negative"><entity charOffset="46:67" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.0" text="candesartan cilexetil" type="Biomedical_Entity"><Normalization><mmtx cui="C0527379" phraseText="Candesartan cilexetil." preferredWord="candesartan cilexetil" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><entity charOffset="0:19" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.1" text="drug drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0013231" phraseText="Drug Label for drug brand ATACAND," preferredWord="Drugs, Non-Prescription" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="26:33" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.2" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="Drug Label for drug brand ATACAND," preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.0"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.0"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.1.e.2"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.10" text="ATACAND is contraindicated in patients who are hypersensitive to candesartan." type="negative"><entity charOffset="0:7" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.10.e.0" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="ATACAND" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><entity charOffset="65:76" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.10.e.1" text="candesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0717550" phraseText="hypersensitive to candesartan." preferredWord="candesartan" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.10.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.10.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11" lineNumber="22" text="Do not co-administer aliskiren with ATACAND in patients with diabetes see DRUG INTERACTIONS (7)." type="regular"><entity charOffset="0:20" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.1" text="Do not co-administer" type="Caution_Interaction"/><entity charOffset="21:30" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with ATACAND" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="61:69" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.3" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes" preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes" preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.4" text="ATACAND" type="Drug"><Normalization><mmtx cui="C0718711" phraseText="aliskiren with ATACAND" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.2"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.3" ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.4" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.11.e.1" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13" lineNumber="24" text="Do not co-administer aliskiren with ATACAND in patients with diabetes. " type="regular"><entity charOffset="0:20" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.1" text="Do not co-administer" type="Caution_Interaction"/><entity charOffset="61:69" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.2" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes." preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes." preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><entity charOffset="21:30" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.3" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with ATACAND" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.4" text="ATACAND" type="Drug"><Normalization><mmtx cui="C0718711" phraseText="aliskiren with ATACAND" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.1"><relations><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.2" ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.4" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.13.e.1" type="Caution_Interaction"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26" text="Candesartan cilexetil given to pregnant rabbits at an oral dose of 3 mg/kg/day (approximately 1.7 times the MRHD on a mg/m2 basis) caused maternal toxicity (decreased body weight and death) but, in surviving dams, had no adverse effects on fetal survival, fetal weight, or external, visceral, or skeletal development. " type="negative"><entity charOffset="198:207" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.0" text="surviving" type="Biomedical_Entity"><Normalization><mmtx cui="C0310255" phraseText="in surviving dams," preferredWord="SURVIVE" semType="phsu"/><RxNorm RxCui="9671"/></Normalization></entity><entity charOffset="124:129" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.1" text="basis" type="Biomedical_Entity"><Normalization><mmtx cui="C1874451" phraseText="on a mg/m2 basis" preferredWord="Basis" semType="phsu"/><RxNorm RxCui="1046801"/></Normalization></entity><entity charOffset="0:21" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.2" text="candesartan cilexetil" type="Biomedical_Entity"><Normalization><mmtx cui="C0527379" phraseText="Candesartan cilexetil" preferredWord="candesartan cilexetil" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.0"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.0"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.26.e.1"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.27" text="No maternal toxicity or adverse effects on fetal development were observed when oral doses up to 1000 mg of candesartan cilexetil/kg/day (approximately 138 times the MRHD on a mg/m2 basis) were administered to pregnant mice." type="negative"><entity charOffset="182:187" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.27.e.0" text="basis" type="Biomedical_Entity"><Normalization><mmtx cui="C1874451" phraseText="on a mg/m2 basis" preferredWord="Basis" semType="phsu"/><RxNorm RxCui="1046801"/></Normalization></entity><entity charOffset="108:129" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.27.e.1" text="candesartan cilexetil" type="Biomedical_Entity"><Normalization><mmtx cui="C0527379" phraseText="oral doses up to 1000 mg of candesartan cilexetil/kg/day" preferredWord="candesartan cilexetil" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.27.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.27.e.0"/></sentence><sentence biomedicalEntities="1" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.33" lineNumber="50" text="Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. " type="irregular"><entity charOffset="12:23" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.33.e.0" text="hypotension" type="Specific_Interaction"/><entity charOffset="127:135" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.33.e.2" text="diuretic" type="Drug_Class"><Normalization><mmtx cui="C0012798" phraseText="depleted as a result of prolonged diuretic therapy," preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.33.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.33.e.0"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.32" text="ATACAND can cause symptomatic hypotension. "><entity charOffset="0:7" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.32.e.0" text="ATACAND" type="Drug"><Normalization><mmtx cui="C0718711" phraseText="ATACAND" preferredWord="Atacand" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.33.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.33.e.2"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.34" text="Patients with symptomatic hypotension may require temporarily reducing the dose of ATACAND, diuretic or both, and volume repletion. " type="negative"><entity charOffset="83:90" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.34.e.0" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="the dose of ATACAND," preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><entity charOffset="92:100" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.34.e.1" text="diuretic" type="Biomedical_Entity"><Normalization><mmtx cui="C0012798" phraseText="diuretic" preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.34.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.34.e.1"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.37" text="The incidence of hypotension leading to drug discontinuation in ATACAND-treated patients was 4.1% compared with 2.0% in placebo-treated patients. " type="negative"><entity charOffset="64:71" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.37.e.0" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="in ATACAND-treated patients" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><entity charOffset="29:36" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.37.e.1" text="leading" type="Biomedical_Entity"><Normalization><mmtx cui="C1442948" phraseText="leading to drug discontinuation" preferredWord="Plumbum metallicum, homeopathic preparation" semType="inch, phsu"/><RxNorm RxCui="1423667"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.37.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.37.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38" lineNumber="51" text="In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, hypotension was reported in 22.6% of patients treated with ATACAND versus 13.8% treated with placebo see DRUG INTERACTIONS (7)." type="regular"><entity charOffset="34:45" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.0" text="candesartan" type="Drug"><Normalization><mmtx cui="C0717550" phraseText="where candesartan" preferredWord="candesartan" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><entity charOffset="82:96" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.1" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="given in addition to ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="98:109" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.2" text="hypotension" type="Specific_Interaction"/><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.1" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.38.e.2" type="Specific_Interaction"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41" text="Hypotension may occur during major surgery and anesthesia in patients treated with angiotensin II receptor antagonists, including ATACAND, due to blockade of the renin-angiotensin system. " type="negative"><entity charOffset="83:118" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.0" text="angiotensin ii receptor antagonists" type="Biomedical_Entity"><Normalization><mmtx cui="C0521942" phraseText="treated with angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="168:179" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.1" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="of the renin-angiotensin system." preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="146:154" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.2" text="blockade" type="Biomedical_Entity"><Normalization><mmtx cui="C3540676" phraseText="due to blockade" preferredWord="Blockade" semType="phsu"/><RxNorm RxCui="1423936"/></Normalization></entity><entity charOffset="47:57" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.3" text="anesthesia" type="Biomedical_Entity"><Normalization><mmtx cui="C0002932" phraseText="anesthesia in patients" preferredWord="Anesthetics" semType="phsu"/><RxNorm RxCui="239756"/></Normalization></entity><entity charOffset="130:137" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.4" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="ATACAND," preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.1"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.2"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.0"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.4"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.1"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.1"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.1"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.2"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.2"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.41.e.4"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.46" text="Patients whose renal function may depend, in part, on the activity of the renin-angiotensin system (e.g., patient with renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion) may be at particular risk of developing oliguria, progressive azotemia or acute renal failure when treated with ATACAND. " type="negative"><entity charOffset="321:328" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.46.e.0" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="treated with ATACAND." preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><entity charOffset="80:91" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.46.e.1" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="of the renin-angiotensin system" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.46.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.46.e.0"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.49" text="The incidence of abnormal renal function (e.g., creatinine increase) leading to drug discontinuation in ATACAND-treated patients was 6.3% compared with 2.9% in placebo-treated patients. " type="negative"><entity charOffset="69:76" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.49.e.0" text="leading" type="Biomedical_Entity"><Normalization><mmtx cui="C1442948" phraseText="leading to drug discontinuation" preferredWord="Plumbum metallicum, homeopathic preparation" semType="inch, phsu"/><RxNorm RxCui="1423667"/></Normalization></entity><entity charOffset="104:111" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.49.e.1" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="in ATACAND-treated patients" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.49.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.49.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50" lineNumber="59" text="In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, the incidence of abnormal renal function (e.g., creatinine increase) was 15% in patients treated with ATACAND versus 9% in patients treated with placebo see DRUG INTERACTIONS (7)." type="regular"><entity charOffset="115:138" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.0" text="abnormal renal function" type="Specific_Interaction"/><entity charOffset="146:165" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.2" text="creatinine increase" type="Specific_Interaction"/><entity charOffset="34:45" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.4" text="candesartan" type="Drug"><Normalization><mmtx cui="C0717550" phraseText="where candesartan" preferredWord="candesartan" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><entity charOffset="82:96" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.5" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="given in addition to ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.0"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.5"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.ddi.2"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.2"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.5" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.50.e.0" type="Specific_Interaction"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.55" text="The incidence of hyperkalemia leading to drug discontinuation in ATACAND-treated patients was 2.4% compared with 0.6% in placebo-treated patients. " type="negative"><entity charOffset="65:72" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.55.e.0" text="atacand" type="Biomedical_Entity"><Normalization><mmtx cui="C0718711" phraseText="in ATACAND-treated patients" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><entity charOffset="30:37" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.55.e.1" text="leading" type="Biomedical_Entity"><Normalization><mmtx cui="C1442948" phraseText="leading to drug discontinuation" preferredWord="Plumbum metallicum, homeopathic preparation" semType="inch, phsu"/><RxNorm RxCui="1423667"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.55.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.55.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56" lineNumber="64" text="In the CHARM-Added program where candesartan or placebo was given in addition to ACE inhibitors, the incidence of hyperkalemia was 9.5% in patients treated with ATACAND versus 3.5% in patients treated with placebo see DRUG INTERACTIONS (7)." type="regular"><entity charOffset="33:44" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.0" text="candesartan" type="Drug"><Normalization><mmtx cui="C0717550" phraseText="In the CHARM-Added program where candesartan" preferredWord="candesartan" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><entity charOffset="81:95" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.1" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="given in addition to ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="114:126" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.2" text="hyperkalemia" type="Specific_Interaction"/><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.2"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.1" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.56.e.2" type="Specific_Interaction"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59" text="Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors). " type="negative"><entity charOffset="59:86" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59.e.0" text="cyclooxygenase-2 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1257954" phraseText="Selective Cyclooxygenase-2 Inhibitors" preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="119049"/></Normalization></entity><entity charOffset="0:38" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59.e.1" text="non-steroidal anti-inflammatory agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003211" phraseText="Non-Steroidal Anti-Inflammatory Agents" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="1005832"/></Normalization></entity><entity charOffset="88:104" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59.e.2" text="cox-2 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1257954" phraseText="(COX-2 Inhibitors" preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="382306"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59.e.0"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.59.e.2"/></sentence><sentence biomedicalEntities="4" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60" lineNumber="70" text="In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. " type="regular"><entity charOffset="141:147" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.1" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="co-administration of NSAIDs," preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="169:185" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.2" text="COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors," preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="382306"/></Normalization></entity><entity charOffset="192:227" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.4" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="239:250" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.5" text="candesartan" type="Drug"><Normalization><mmtx cui="C0717550" phraseText="candesartan," preferredWord="candesartan" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><entity charOffset="266:297" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.7" text="deterioration of renal function" type="Specific_Interaction"/><entity charOffset="20:27" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.8" text="elderly" type="SPAN"/><entity charOffset="29:44" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.9" text="volume-depleted" type="SPAN"/><entity charOffset="92:118" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.10" text="compromised renal function" type="SPAN"/><entity charOffset="318:337" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.12" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="possible acute renal failure." preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><classClassMembership drugClass="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.2"/><drugClassMembership drug="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.5" drugClass="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.4"/><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.7"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.4"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.9"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.10"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.ddi.2"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.12"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.4"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.9"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.10"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.8, Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.9, Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.10" ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.1" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.4" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.60.e.7" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62" lineNumber="70" text="Monitor renal function periodically in patients receiving candesartan and NSAID therapy." type="regular"><entity charOffset="0:7" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.1" text="Monitor" type="Caution_Interaction"/><entity charOffset="58:69" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.2" text="candesartan" type="Drug"><Normalization><mmtx cui="C0717550" phraseText="candesartan" preferredWord="candesartan" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><entity charOffset="74:79" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.3" text="NSAID" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAID therapy." preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.1"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.3" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.62.e.1" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="4" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63" lineNumber="71" text="The antihypertensive effect of angiotensin II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors." type="regular"><entity charOffset="111:117" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.1" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="attenuated by NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="128:154" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.2" text="selective COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors." preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="1431714"/></Normalization></entity><entity charOffset="31:66" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.4" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="The antihypertensive effect of angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="78:89" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.5" text="candesartan" type="Drug"><Normalization><mmtx cui="C0717550" phraseText="candesartan" preferredWord="candesartan" semType="phsu, orch"/><RxNorm RxCui="214354"/></Normalization></entity><entity charOffset="4:27|97:107" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.7" text="antihypertensive effect attenuated" type="Specific_Interaction"/><classClassMembership drugClass="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.2"/><drugClassMembership drug="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.5" drugClass="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.4"/><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.7"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.1" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.63.e.7" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65" lineNumber="73" text="Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists. " type="regular"><entity charOffset="11:29|38:52" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.1" text="increases in serum concentrations" type="Increase_Interaction"/><entity charOffset="165:200" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.2" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="and with some angiotensin II receptor antagonists." preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="135:149" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.3" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="with ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="30:37" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.4" text="lithium" type="Drug"><Normalization><mmtx cui="C1441405" phraseText="Reversible increases in serum lithium concentrations" preferredWord="Lithium.serum" semType="phsu, elii"/><RxNorm RxCui="1428998"/></Normalization></entity><entity charOffset="57:65" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.6" text="toxicity" type="Increase_Interaction"/><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.ddi.2"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.2" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.1" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.3" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.1" type="Increase_Interaction"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.65.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66" lineNumber="73" text="An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND. " type="regular"><entity charOffset="3:20|29:42" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.1" text="increase in serum concentration" type="Increase_Interaction"/><entity charOffset="111:118" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.2" text="ATACAND" type="Drug"><Normalization><mmtx cui="C0718711" phraseText="with ATACAND." preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><entity charOffset="21:28" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.3" text="lithium" type="Drug"><Normalization><mmtx cui="C1441405" phraseText="An increase in serum lithium concentration" preferredWord="Lithium.serum" semType="phsu, elii"/><RxNorm RxCui="1428998"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.1"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.2" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.1" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.67" lineNumber="73" text="Monitor serum lithium levels." type="irregular"><entity charOffset="0:7" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.67.e.1" text="Monitor" type="Caution_Interaction"/><entity charOffset="14:21" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.67.e.2" text="lithium" type="Drug"><Normalization><mmtx cui="C0023870" phraseText="Monitor serum lithium levels." preferredWord="Lithium" semType="phsu, elii"/><mmtx cui="C0023870" phraseText="Monitor serum lithium levels." preferredWord="Lithium" semType="phsu, elii"/><RxNorm RxCui="1428998"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.67.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.67.e.1"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66" text="An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND. "><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.66.e.2"/></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.67.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.67.e.2"/></sentence><sentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.68" text="Dual Blockade of the Renin-Angiotensin System (RAS)" type="negative"><entity charOffset="5:13" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.68.e.0" text="blockade" type="Biomedical_Entity"><Normalization><mmtx cui="C3540676" phraseText="Dual Blockade of the Renin-Angiotensin System" preferredWord="Blockade" semType="phsu"/><RxNorm RxCui="1423936"/></Normalization></entity><entity charOffset="27:38" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.68.e.1" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="Dual Blockade of the Renin-Angiotensin System" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.68.e.0" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.68.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69" lineNumber="75" text="Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. " type="irregular"><entity charOffset="128:139" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.1" text="hypotension" type="Specific_Interaction"/><entity charOffset="61:75" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="80:89" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="30:59" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4" text="angiotensin receptor blockers" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin receptor blockers," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><mmtx cui="C0815017" phraseText="with angiotensin receptor blockers," preferredWord="Angiotensin Receptor Antagonists" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="141:153" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.6" text="hyperkalemia" type="Specific_Interaction"/><entity charOffset="159:184" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.8" text="changes in renal function" type="Specific_Interaction"/><entity charOffset="196:215" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.10" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4"/></relation><relation type="hasObject"><labelDrug text="ATACAND"/><normalization><mmtx><preferredWord>Atacand</preferredWord><phraseText>aliskiren with ATACAND</phraseText><cuiCode>C0718711</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.ddi.2"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4"/></relation><relation type="hasObject"><labelDrug text="ATACAND"/><normalization><mmtx><preferredWord>Atacand</preferredWord><phraseText>aliskiren with ATACAND</phraseText><cuiCode>C0718711</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.ddi.3"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.8"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4"/></relation><relation type="hasObject"><labelDrug text="ATACAND"/><normalization><mmtx><preferredWord>Atacand</preferredWord><phraseText>aliskiren with ATACAND</phraseText><cuiCode>C0718711</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.ddi.4"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.10"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4"/></relation><relation type="hasObject"><labelDrug text="ATACAND"/><normalization><mmtx><preferredWord>Atacand</preferredWord><phraseText>aliskiren with ATACAND</phraseText><cuiCode>C0718711</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2"/><pair ddi="false" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.3"/><pair ddi="true" e1="labelDrug" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.69.e.4"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70" lineNumber="75" text="Closely monitor blood pressure, renal function and electrolytes in patients on ATACAND and other agents that affect the RAS." type="regular"><entity charOffset="8:15" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.1" text="monitor" type="Caution_Interaction"/><entity charOffset="97:123" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.2" text="agents that affect the RAS" type="Drug_Class"><Normalization><mmtx cui="C1254351" phraseText="other agents" preferredWord="Pharmacologic Substance" semType="phsu"/><RxNorm RxCui="126263"/></Normalization></entity><entity charOffset="79:86" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.3" text="ATACAND" type="Drug"><Normalization><mmtx cui="C0718711" phraseText="on ATACAND" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.2" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.70.e.1" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71" lineNumber="76" text="Do not co-administer aliskiren with ATACAND in patients with diabetes. " type="regular"><entity charOffset="0:20" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.1" text="Do not co-administer" type="Caution_Interaction"/><entity charOffset="21:30" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with ATACAND" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="61:69" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.3" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes." preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes." preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.4" text="ATACAND" type="Drug"><Normalization><mmtx cui="C0718711" phraseText="aliskiren with ATACAND" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.4"/></relation><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.3"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.3" ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.2" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.4" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.71.e.1" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72" lineNumber="76" text="Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR 60 ml/min) see CONTRAINDICATIONS (4)." type="regular"><entity charOffset="0:5" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.1" text="Avoid" type="Caution_Interaction"/><entity charOffset="53:69" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.2" text="renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><entity charOffset="13:22" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.3" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="use of aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="28:35" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.4" text="ATACAND" type="Drug"><Normalization><mmtx cui="C0718711" phraseText="with ATACAND" preferredWord="Atacand" semType="phsu, orch"/><RxNorm RxCui="215458"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.1"><relations><relation type="hasContext"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.2" ddi="true" e1="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.3" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.4" trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.1" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73" lineNumber="79" text="&lt;item&gt;Lithium: Reversible increases in serum lithium concentrations and toxicity (7)." type="irregular"><entity charOffset="26:44|53:67" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.1" text="increases in serum concentrations" type="Increase_Interaction"/><entity charOffset="45:52" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.2" text="lithium" type="Drug"><Normalization><mmtx cui="C1441405" phraseText="Reversible increases in serum lithium concentrations" preferredWord="Lithium.serum" semType="phsu, elii"/><RxNorm RxCui="1428998"/></Normalization></entity><entity charOffset="72:80" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.4" text="toxicity" type="Increase_Interaction"/><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.1"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.2"/></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72" text="Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR 60 ml/min) see CONTRAINDICATIONS (4)."><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.4"/></ellipsisSentence></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.ddi.2"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.4"><relations><relation type="hasObject"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73.e.2"/></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72" text="Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR 60 ml/min) see CONTRAINDICATIONS (4)."><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.4"/></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="1" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74" lineNumber="81" text="&lt;item&gt;NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7)." type="irregular"><entity charOffset="68:99" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.1" text="loss of antihypertensive effect" type="Specific_Interaction"/><entity charOffset="6:12" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.2" text="NSAIDS" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="&gt;NSAIDS" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="47:63" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.4" text="renal impairment" type="Specific_Interaction"><Normalization><mmtx cui="C0035078" phraseText="lead to increased risk of renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="lead to increased risk of renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.2"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72" text="Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR 60 ml/min) see CONTRAINDICATIONS (4)."><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.4"/></ellipsisSentence><middleSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73" text="&lt;item&gt;Lithium: Reversible increases in serum lithium concentrations and toxicity (7)."/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.ddi.2"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.2"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72" text="Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR 60 ml/min) see CONTRAINDICATIONS (4)."><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.72.e.4"/></ellipsisSentence><middleSentence id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.73" text="&lt;item&gt;Lithium: Reversible increases in serum lithium concentrations and toxicity (7)."/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.74.e.2"/></sentence><sentence biomedicalEntities="1" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75" lineNumber="83" text="&lt;item&gt;Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7)" type="irregular"><entity charOffset="91:102" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.1" text="hypotension" type="Specific_Interaction"/><entity charOffset="11:53" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.2" text="inhibition of the renin-angiotensin system" type="Drug_Class"><Normalization><mmtx cui="C0035100" phraseText="&gt;Dual inhibition of the renin-angiotensin system" preferredWord="Chymosin" semType="phsu, aapp, enzy"/><mmtx cui="C0003018" phraseText="&gt;Dual inhibition of the renin-angiotensin system" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="986536"/></Normalization></entity><entity charOffset="108:120" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.4" text="hyperkalemia" type="Specific_Interaction"/><entity charOffset="73:89" id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.6" text="renal impairment" type="Specific_Interaction"><Normalization><mmtx cui="C0035078" phraseText="Increased risk of renal impairment," preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="Increased risk of renal impairment," preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.ddi.1"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.2"/></relation><relation type="hasObject"><labelDrug text="ATACAND"/><normalization><mmtx><preferredWord>Atacand</preferredWord><phraseText>aliskiren with ATACAND</phraseText><cuiCode>C0718711</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.ddi.2"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.2"/></relation><relation type="hasObject"><labelDrug text="ATACAND"/><normalization><mmtx><preferredWord>Atacand</preferredWord><phraseText>aliskiren with ATACAND</phraseText><cuiCode>C0718711</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.ddi.3"><interaction trigger="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.2"/></relation><relation type="hasObject"><labelDrug text="ATACAND"/><normalization><mmtx><preferredWord>Atacand</preferredWord><phraseText>aliskiren with ATACAND</phraseText><cuiCode>C0718711</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.a73e1339-9643-4eea-2cbe-e879c88fb50e.s.75.e.2"/></sentence><positiveExamples number="21"/><negativeExamples number="30"/></document>